Brain and Mind Centre, Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW 2050, Australia.
Cells. 2023 Feb 25;12(5):739. doi: 10.3390/cells12050739.
Multiple system atrophy (MSA) is a debilitating movement disorder with unknown etiology. Patients present characteristic parkinsonism and/or cerebellar dysfunction in the clinical phase, resulting from progressive deterioration in the nigrostriatal and olivopontocerebellar regions. MSA patients have a prodromal phase subsequent to the insidious onset of neuropathology. Therefore, understanding the early pathological events is important in determining the pathogenesis, which will assist with developing disease-modifying therapy. Although the definite diagnosis of MSA relies on the positive post-mortem finding of oligodendroglial inclusions composed of α-synuclein, only recently has MSA been verified as an oligodendrogliopathy with secondary neuronal degeneration. We review up-to-date knowledge of human oligodendrocyte lineage cells and their association with α-synuclein, and discuss the postulated mechanisms of how oligodendrogliopathy develops, oligodendrocyte progenitor cells as the potential origins of the toxic seeds of α-synuclein, and the possible networks through which oligodendrogliopathy induces neuronal loss. Our insights will shed new light on the research directions for future MSA studies.
多系统萎缩(MSA)是一种病因不明的使人衰弱的运动障碍。在临床阶段,由于黑质纹状体和橄榄脑桥小脑区域的进行性恶化,患者表现出特征性的帕金森病和/或小脑功能障碍。MSA 患者在神经病理学隐匿性发作后有前驱期。因此,了解早期的病理事件对于确定发病机制很重要,这将有助于开发疾病修饰疗法。尽管 MSA 的明确诊断依赖于由 α-突触核蛋白组成的少突胶质细胞包含体的阳性尸检发现,但直到最近,MSA 才被确认为伴有继发性神经元变性的少突胶质细胞病。我们回顾了有关人类少突胶质细胞谱系细胞及其与 α-突触核蛋白的关联的最新知识,并讨论了少突胶质细胞病发展的假定机制、少突胶质前体细胞作为 α-突触核蛋白毒性种子的潜在起源,以及少突胶质细胞病诱导神经元丢失的可能网络。我们的见解将为未来 MSA 研究的研究方向提供新的思路。